The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, E-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Associate Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, E-mail: waddfour@charter.net.
Get full access to this article
View all access options for this article.
References
1.
MillwardM.J., BoyerM.J., LehnertM.. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Onc.2003; 14: 449–454.
2.
MavroudisD., AlexopoulosA., MalamosN.. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. Oncology.2003; 64: 207–212.
3.
FossellaF., PereiraJ., von PawelJ.. Randomized, multinational, phase III study of docetaxel plus platinum combinations, versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol.2003; 21: 3016–3024.
4.
PerezE.A., SumanV.J., FitchT.R.. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology.2005; 69: 117–121.
5.
BelaniC.P., FossellaF.Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced non-small cell lung carcinoma (TAX 326). Cancer.2005; 104: 2766–2774.
6.
JohnsonF.M., GardenA., PalmerJ.L.. Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer.2004; 100: 991–998.
7.
RamalingamS., DobbsT.W., EinzigA.I.. Carboplatin and docetaxel in advanced non-small cell lung cancer: results of a multicenter phase II study. Cancer Chemother Pharmacol.2004; 33: 439–444.
8.
VaseyP.A., JaysonG.C., GordonA.. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Nat Can Inst.2004; 96: 1682–1691.
9.
NagaoS., FujiwaraK., OdaT.. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol.2005; 96: 805–809.
10.
HurleyJ., ReisI., SilvaO.. Weekly docetaxel/carboplatin as primary systemic therapy for her2-negative locally advanced breast cancer. Clin Breast Caner.2005; 5: 447–454.
11.
SchwartzD.L., MontgomeryR.B., YuehB.. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of head and neck. Cancer.2005; 103: 2534–2543.
12.
PegramM.D., PienkowskiT., NorthfeltD.W.. Results of two open-labeled, multicenter phase 2 studies of docetaxel, platinum salts, and trastuzumab in Her2-positive breast cancer. J Nat Cancer Inst.2004; 96: 759–769.
13.
PfistererJ., du BoisA., WagnerU.. Docetaxel and carboplatin as first–line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gyn Onc.2004; 92: 949–956.
14.
WirthL.J., LuccaJ., OstlerP.. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage 3 non-small cell lung cancer: a phase I study. Clin Can Res.2003; 9: 1698–1704.
15.
ZarogoulidisK., KontakiotisT., HatziapostolouP.. A phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer.2001; 32: 281–287.
16.
BelaniC.P., EinzigA., BonomiP.. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol.2000; 11: 673–678.
17.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. v.2.2006. Available at: http://www.nccn.org/. Accessed July 24, 2006.
18.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Ovarian cancer. v.1.2006. Available at: http://www.nccn.org/. Accessed July 24, 2006.
19.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44: 124–130.
20.
CohenM.R., SmetzerJ.1999 (2 June). Preparing for a damaging medication error. ISMP Medication Safety Alert! Vol 4 (No. 14).
21.
SavareseD., TaplinM.E., HalabiS., HarsV., KreisW., VogelzegangN.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol.1999; 26(5 suppl 17): 39–44.
22.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
23.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines - Antiemesis. V.2.2006. Available at: http://www.nccn.org/. Accessed September 10, 2006.
24.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24: 2932–2947.
25.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. Available at http://www.mascc.org/. Accessed October 1, 2006.
26.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23: 1289–1294.
27.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
28.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9: 381–385.
29.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85: 1099–1101.
30.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119: 350–354.
31.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2: 177–183.
32.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
33.
DuBoisA., VachW., KiechleM., Cramer-GiraudU., MeerpohlH.G.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(Suppl 1): 46–50.
34.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–158.
ZanottiK.M., MarkmamM.Prevention and management of antineoplastic-induced Hypersensitivity reactions. Drug Saf.2001; 24: 767–779.
37.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24: 3187–3205.
38.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. v.1.2006. Available at: http://www.nccn.org/. Accessed September 20, 2006.
39.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–1799.
40.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–405.
41.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
42.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
43.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
